Therapeutics MD’s Annovera (Segesterone Acetate/Ethinyl Estradiol) Receives FDA Approval for the Prevention of Pregnancy

 Therapeutics MD’s Annovera (Segesterone Acetate/Ethinyl Estradiol) Receives FDA Approval for the Prevention of Pregnancy

Therapeutics MD’s Annovera (Segesterone Acetate/Ethinyl Estradiol) Receives FDA Approval for the Prevention of Pregnancy

Shots:

  • The approval is based on 17 clinical trials results assessing Annovera in 2,308 women aged ≤35yrs
  • The study demonstrated in prevention of 97.3% pregnancy, Pearl Index (PI) 2.98/100 women with overall satisfaction rate is 89%
  • Annovera is a combination of estrogen (ethinyl estradiol, 0.15 mg/day) & Nestorone (segesterone acetate,0.013 mg/day) used for prevention of ovulation for a year (13 cycle) without any medical help

Click here to read full press release/ article | Ref: Therapeutics MD | Image: Benzinga

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post